頁籤選單縮合
題 名 | Hormonal Postcoital Contraception=行房後荷爾蒙避孕方法之回顧 |
---|---|
作 者 | 林德熙; 蘇聰賢; 陳鴻生; | 書刊名 | 中華民國婦產科醫學會會刊雜誌 |
卷 期 | 38:1 1999.03[民88.03] |
頁 次 | 頁11-19 |
分類號 | 417.129 |
關鍵詞 | 行房後避孕方法; 緊急避孕法; Postcoital contraception; Emergency contraception; RU486; Mifepristone; Morning-after pills; Yuzpe regimen; Danazol; |
語 文 | 英文(English) |
中文摘要 | 本文是針對行房後荷爾蒙避孕方法的原理、效果和副作用做一整體性回顧。 應用 MEDLINE 搜尋最近 30 年( 1967 一 1996 )行房後荷爾蒙避孕方法,共得到 28 篇相關文 獻得以比較。到目前為止,共有 5 種行房後荷爾蒙避孕方法,分別是:RU486 (行房後 72 小時內給予 600 mg 一次),estro-progestin ( Yuzperegimen:行房後 72 小時內, 隔 12/J@ 時給予 100 u g ethinylestradiol + Imgdl-norgestrel/0.5 mg levonorgestrel , 共兩次), 高劑量 ethinylestradiol (行房後 72 小時內, 每天給予 5 mg ethinylestradiol,共 5 劑),高劑量 progestin (行房後 48 小時內,每隔 12 小時給 予兩劑 0.75 mg levonorgestrel ), 和 danazol (行房後 72 小時內,每隔 12 小時給 予 400 mg danazol, 2-3 次 ) 。 在效果方面, 分別是 RU486, 95.6 %; estro-progestin'72.6 %; 高劑量 ethinylestradiol, 62.8 %; 高劑量 progestin, 49.5 %; 800 mg danazol, 71.5 %和 1200 mg danazol 69.3 %有效。 但其中高劑量 ethinylestradiol 和 Yuzperegimen 引起較厲害的噁心 (59.4 %和 36.1 %)、 嘔吐( 26.1 %和 14.0 %)和乳房腫脹( 23.7 %和 8 . 80 %)的副作用。比較這 28 篇文獻 ,可了解 RU486 可得到最佳避孕效果和最輕的副作用,而且 RU486 只需服用一次,在使用 上也最方便。 |
英文摘要 | Objective: Postcoital contraception has been used to prevent unintended pregnancies after unprotected intercourse since the late 1960s. This article reviews information on currently available postcoital contraceptive methods, comparing their efficacy and side effects. Methods: A total of 28 published studies, from 1967 through 1996, were identified. Five main post- coital contraceptive methods, including mifepristone (RU486), estro-progestin preparations (Yuzpe regimen: using a total dose of 0.2 mg of ethinylestradiol plus either 2.0 mg norgestrel or 1.0 mg of levonorgestrel) , high-dose ethinylestradiol, dt-norgestrel and danazol, were analyzed in terms of the schedule of treatment, numbers of patients, numbers of failures and expected pregnancies, calculation of proportionate reduction in probable conception rate, and general methodological issues. Results: The effectiveness was 95.6% for RU486, 72.6% for estro-progestin preparations, 62.8% for high-dose ethinylestradiol, 49.5% for high-dose dl-norgestrel, and 71.5 and 69.3% for 800 mg and 1200 mg danazol, respectively. More side effects were noted in the Yuzpe and high-dose ethinylestradiol groups (nausea 36.1 and 59.4%, vomiting 14.0 and 26.1%, breast tenderness 8.8 and 23.7%, respectively). Side effects of the remainin@methods were reported as: RU486: nausea 34.2%, vomiting 2.4%, breast tenderness 23.6%: high-dosage levonorgestrel: nausea 13.3%, vomiting 1.8%, breast tenderness 6.0%; and danazol: nausea 11.5%, vomiting 1.5%, breast tenderness 10.4%. The effectiveness and side effects among these five treatments were all significantly different. Conclusions: This review suggests that RU486 is a more efficacious form of post-coital contraception than the other methods because of its high effectiveness, relatively few side effects and the convenience of single dosing. |
本系統中英文摘要資訊取自各篇刊載內容。